Literature DB >> 2312149

Anti-CD3 antibody-induced expression of both p55 and p75 chains of the high affinity interleukin-2 receptor on human T lymphocytes is inhibited by cyclosporin A.

B M Foxwell1, J Simon, J J Herrero, D Taylor, G Woerly, D Cantrell, B Ryffel.   

Abstract

The inhibitory effect of cyclosporin (CsA) was investigated on human lymphocytes stimulated by anti-T-cell antibodies (anti-CD3 and -CD2) or mitogenic lectins. Whereas inhibition of cell proliferation (50%) occurred at 10 ng/ml CsA after cell activation via CD3 or CD2, higher CsA concentrations (300 ng/ml) were necessary to inhibit lectin-mediated cell activation (PHA, Con A). Exogenous recombinant interleukin-2 (rIL-2) partially reversed the inhibitory effect on antibody-stimulated cells only; however, at higher CsA concentrations (300 ng/ml) proliferation was again inhibited. Thus, CsA affected IL-2R expression and/or function at higher concentrations (300 ng/ml). CsA had no effect on receptor function as measured on IL-2-dependent cell growth of CTLL cells or preactivated lymphocytes. However, CsA inhibited both high and low affinity receptor expression as shown by [125I]IL-2 equilibrium binding studies on anti-CD3-stimulated cells. Cross-linking studies revealed that both p55 (TAC) and p75 chains of the IL-2R were not induced at low CsA concentrations (10 ng/ml). However, addition of rIL-2 reversed CsA inhibition of IL-2R expression. It is concluded that CsA, at least in anti-CD3-stimulated cells, inhibits IL-2R expression and cell proliferation with similar potency. Exogenous rIL-2 reverses CsA inhibition of IL-2R expression. This might be due to binding of rIL-2 to receptors which escape CsA inhibition, thereby up-regulating receptor expression which is drug resistant.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2312149      PMCID: PMC1385727     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  32 in total

1.  Phytohemagglutinin binds to the 20-kDa molecule of the T3 complex.

Authors:  M A Valentine; C D Tsoukas; G Rhodes; J H Vaughan; D A Carson
Journal:  Eur J Immunol       Date:  1985-08       Impact factor: 5.532

2.  Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene.

Authors:  J M Depper; W J Leonard; C Drogula; M Krönke; T A Waldmann; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

3.  Interleukin 2 (IL 2) up-regulates its own receptor on a subset of human unprimed peripheral blood lymphocytes and triggers their proliferation.

Authors:  A Harel-Bellan; J Bertoglio; A Quillet; C Marchiol; H Wakasugi; Z Mishall; D Fradelizi
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

4.  Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen.

Authors:  R J Robb; W C Greene; C M Rusk
Journal:  J Exp Med       Date:  1984-10-01       Impact factor: 14.307

5.  T cell triggering by lectins. I. Requirements for interleukin 2 production; lectin concentration determines the accessory cell dependency.

Authors:  E E Roosnek; M C Brouwer; L A Aarden
Journal:  Eur J Immunol       Date:  1985-07       Impact factor: 5.532

6.  The mitogenic lectin from Phaseolus vulgaris does not recognize the T3 antigen of human T lymphocytes.

Authors:  J M Kanellopoulos; S De Petris; G Leca; M J Crumpton
Journal:  Eur J Immunol       Date:  1985-05       Impact factor: 5.532

7.  T cell triggering by lectins. II. Stimuli for induction of interleukin 2 responsiveness and interleukin 2 production differ only in quantitative aspects.

Authors:  E E Roosnek; M C Brouwer; L A Aarden
Journal:  Eur J Immunol       Date:  1985-07       Impact factor: 5.532

8.  Monoclonal antibody OKT11A inhibits and recombinant interleukin 2 (IL 2) augments expression of IL 2 receptors at a pretranslational level.

Authors:  J C Reed; W C Greene; R G Hoover; P C Nowell
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

9.  Induction of interleukin 2 messenger RNA inhibited by cyclosporin A.

Authors:  J F Elliott; Y Lin; S B Mizel; R C Bleackley; D G Harnish; V Paetkau
Journal:  Science       Date:  1984-12-21       Impact factor: 47.728

10.  Lymphokine and nonlymphokine mRNA levels in stimulated human T cells. Kinetics, mitogen requirements, and effects of cyclosporin A.

Authors:  A Granelli-Piperno; L Andrus; R M Steinman
Journal:  J Exp Med       Date:  1986-04-01       Impact factor: 14.307

View more
  6 in total

1.  The clinical and immunological effects of cyclosporin A on patients with rheumatoid arthritis.

Authors:  D M Chang; S F Chiao
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

Review 2.  Clinical use of cyclosporin in rheumatoid arthritis.

Authors:  C Richardson; P Emery
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 3.  Mechanism of action of cyclosporin in rheumatoid arthritis.

Authors:  J Bentin
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

4.  Induced gene expression of the hypusine-containing protein eukaryotic initiation factor 5A in activated human T lymphocytes.

Authors:  D Bevec; H Klier; W Holter; E Tschachler; P Valent; F Lottspeich; T Baumruker; J Hauber
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

5.  Spontaneous lymphocyte proliferation in human T-cell lymphotropic virus type I (HTLV-I) and HTLV-II infection: T-cell subset responses and their relationships to the presence of provirus and viral antigen production.

Authors:  H E Prince; J York; J Golding; S M Owen; R B Lal
Journal:  Clin Diagn Lab Immunol       Date:  1994-05

6.  Mutually exclusive regulation of T cell survival by IL-7R and antigen receptor-induced signals.

Authors:  Paul Koenen; Susanne Heinzel; Emma M Carrington; Lina Happo; Warren S Alexander; Jian-Guo Zhang; Marco J Herold; Clare L Scott; Andrew M Lew; Andreas Strasser; Philip D Hodgkin
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.